Sita Yanamadala, MD
Nephrology · Lynwood, CANPI 1821049255
Payments from drug & device makers
Across 179 payments — averaging $2452.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$403K
- Gilead$15K
- Alnylam Pharmaceuticals Inc.$8K
- Eli Lilly$8K
- Novo Nordisk AS$5K
- Amgen$89
- plus $106 from 5 others
Across 2 payments — averaging $2469.61 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$5K
What the payments were for
- Food & beverage$18193%
- Education$147%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 114 | $402,942 |
| Gilead | 5 | $14,682 |
| Alnylam Pharmaceuticals Inc. | 4 | $8,490 |
| Eli Lilly | 1 | $7,656 |
| Novo Nordisk AS | 48 | $4,943 |
| Amgen | 2 | $89 |
| Ardelyx, Inc. | 1 | $27 |
| GSK | 1 | $26 |
| Fresenius USA Marketing, Inc. | 1 | $24 |
| Akebia Therapeutics Inc | 1 | $15 |
| Calliditas Therapeutics US Inc. | 1 | $14 |
How this compares
$438,907 in reported general payments places this provider in the 95th percentile of 1,341 nephrology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 298 | $184,746 |
| Sevelamer Hcl | 27 | $55,229 |
| ProcritEpoetin Alfa | 47 | $44,733 |
| DapagliflozinDapagliflozin Propanediol | 71 | $38,452 |
| KerendiaFinerenone | 13 | $17,189 |
| Sevelamer Carbonate | 70 | $13,413 |
| RayaldeeCalcifediol | 11 | $12,528 |
| ProsolParenteral Amino Acid 20% No.1 | 66 | $10,594 |
| Calcium Acetate | 42 | $4,917 |
| Midodrine Hcl | 15 | $815 |
| Furosemide | 70 | $804 |
| Gentamicin Sulfate | 18 | $774 |
| Potassium Chloride | 48 | $598 |
| Hydralazine Hcl | 42 | $318 |
| Allopurinol | 42 | $261 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Lynwood
- Ramon GuadizLynwood$865K
- Anjay RastogiLos Angeles$6.3M
- Aamir JamalSan Dimas$5.5M
- Mohamed El-ShahawyLos Angeles$4.4M
- Kalpesh PatelCalabasas$3.6M
- Jehad HaggiagiMission Hills$3.6M
- Malvin YanSouth Gate$3.3M
- Sohan DuaNorthridge$3.2M
- Richard LafayetteStanford$3M
- Anant DesaiGranada Hills$2.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.